Non-adherence to cardiometabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus
Diabetologia · 2024
DOI: 10.1007/s00125-024-06149-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, 2024. Verfasst von Sara Denicolò und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria. sara.denicolo@i-med.ac.at. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Medication Adherence, Tandem Mass Spectrometry. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020, European Union, Innovative Medicines Initiative 2 Joint Undertaking.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/hypothesis Non-adherence to medication is a frequent barrier in the treatment of patients with type 2 diabetes mellitus, potentially limiting the effectiveness of evidence-based treatments. Previous studies have mostly relied on indirect adherence measures to analyse outcomes based on adherence. The aim of this study was to use LC-MS/MS in urine—a non-invasive, direct and objective measure—to assess non-adherence to cardiometabolic drugs and analyse its association with kidney and cardiovascular outcomes.
Methods
This cohort study includes 1125 participants from the PROVALID study, which follows patients with type 2 diabetes mellitus at the primary care level. Baseline urine samples were tested for 79 cardiometabolic drugs and metabolites thereof via LC-MS/MS. An individual was classified as totally adherent if markers for all drugs were detected, partially non-adherent when at least one marker for one drug was detected, and totally non-adherent if no markers for any drugs were detected. Non-adherence was then analysed in the context of cardiovascular (composite of myocardial infarction, stroke and cardiovascular death) and kidney (composite of sustained 40% decline in eGFR, sustained progression of albuminuria, kidney replacement therapy and death from kidney failure) outcomes.
Results
Of the participants, 56.3% were totally adherent, 42.0% were partially non-adherent, and 1.7% were totally non-adherent to screened cardiometabolic drugs. Adherence was highest to antiplatelet and glucose-lowering agents and lowest to lipid-lowering agents. Over a median (IQR) follow-up time of 5.10 (4.12–6.12) years, worse cardiovascular outcomes were observed with non-adherence to antiplatelet drugs (HR 10.13 [95% CI 3.06, 33.56]) and worse kidney outcomes were observed with non-adherence to antihypertensive drugs (HR 1.98 [95% CI 1.37, 2.86]). Conclusions/interpretation This analysis shows that non-adherence to cardiometabolic drug regimens is common in type 2 diabetes mellitus and negatively affects kidney and cardiovascular outcomes. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria. sara.denicolo@i-med.ac.at.
- Institute of Legal Medicine and Core Facility Metabolomics, Medical University Innsbruck, Innsbruck, Austria.
- Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- International Nephrology Research and Training Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary.
- Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland.
Förderung
- Horizon 2020
- European Union
- Innovative Medicines Initiative 2 Joint Undertaking
- AbbVie
- University of Innsbruck and Medical University of Innsbruck
Zitieren
APA
Denicolò, S., Reinstadler, V., Keller, F., Thöni, S., Eder, S., Heerspink, H. J. L., Rosivall, L., Wiecek, A., Mark, P. B., Perco, P., Leierer, J., Kronbichler, A., Oberacher, H., & Mayer, G. (2024). Non-adherence to cardiometabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus. Diabetologia. https://doi.org/10.1007/s00125-024-06149-w
Vancouver
Denicolò S, Reinstadler V, Keller F, Thöni S, Eder S, Heerspink HJL, et al. Non-adherence to cardiometabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus. Diabetologia. 2024. doi:10.1007/s00125-024-06149-w
BibTeX
@article{Denicol2024,
author = {Denicolò, Sara and Reinstadler, Vera and Keller, Felix and Thöni, Stefanie and Eder, Susanne and Heerspink, Hiddo J L and Rosivall, László and Wiecek, Andrzej and Mark, Patrick B and Perco, Paul and Leierer, Johannes and Kronbichler, Andreas and Oberacher, Herbert and Mayer, Gert},
title = {Non-adherence to cardiometabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus},
journal = {Diabetologia},
year = {2024},
doi = {10.1007/s00125-024-06149-w}
}
EUVIMED